Corvus Pharmaceuticals (NASDAQ:CRVS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research note published on Saturday. The brokerage issued a sell rating on the stock.

Corvus Pharmaceuticals Stock Performance

Corvus Pharmaceuticals stock remained flat at $0.74 on Friday. 154,130 shares of the company’s stock were exchanged, compared to its average volume of 93,650. The firm has a market cap of $34.22 million, a PE ratio of -0.84 and a beta of 1.04. Corvus Pharmaceuticals has a 52-week low of $0.61 and a 52-week high of $2.11. The company’s fifty day moving average is $0.79 and its two-hundred day moving average is $0.85.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Corvus Pharmaceuticals by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 1,267,752 shares of the company’s stock worth $2,079,000 after acquiring an additional 36,002 shares during the last quarter. Renaissance Technologies LLC lifted its position in Corvus Pharmaceuticals by 1.3% during the 3rd quarter. Renaissance Technologies LLC now owns 975,519 shares of the company’s stock worth $798,000 after acquiring an additional 12,587 shares during the last quarter. Discovery Capital Management LLC CT acquired a new position in Corvus Pharmaceuticals during the 4th quarter worth $466,000. Telemetry Investments L.L.C. increased its holdings in shares of Corvus Pharmaceuticals by 13.5% during the 3rd quarter. Telemetry Investments L.L.C. now owns 522,009 shares of the company’s stock worth $427,000 after purchasing an additional 61,906 shares during the period. Finally, Two Sigma Advisers LP increased its holdings in shares of Corvus Pharmaceuticals by 28.6% during the 3rd quarter. Two Sigma Advisers LP now owns 480,100 shares of the company’s stock worth $393,000 after purchasing an additional 106,700 shares during the period. Institutional investors and hedge funds own 47.45% of the company’s stock.

About Corvus Pharmaceuticals

(Get Rating)

Corvus Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor.